Voices
Mostafa Faisal: ASCT Remains Effective for Chemotherapy-Sensitive Late Relapse in DLBCL
Mostafa Faisal/ LinkedIn

Mostafa Faisal: ASCT Remains Effective for Chemotherapy-Sensitive Late Relapse in DLBCL

Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared on X:

“ASCT in late-relapsed DLBCL: CIBMTR study of 182 patients achieving CR/PR to salvage therapy.

  • 3-year OS 67.6%, PFS 50.6%, relapse 43.9%.
  •  PR versus CR before ASCT predicted inferior PFS (HR 1.41).

ASCT remains effective for chemotherapy-sensitive late relapse (>12 m).”

Title: Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma

Authors: Lorenzo Iovino, Ningxin Ma, Mohamed A. Kharfan-Dabaja, Alex F. Herrera, Craig S. Sauter, Mehdi Hamadani, Peter A. Riedell, Ajay K. Gopal, Leona Holmberg, Qian Vicky Wu, Sonali M. Smith, Mazyar Shadman

Read the Full Article on Blood Neoplasia

Mostafa Faisal: ASCT Remains Effective for Chemotherapy-Sensitive Late Relapse in DLBCL

You can also read: AbbVie and Genmab Report 51% Reduction in Progression With Epcoritamab Plus R-CHOP in Diffuse Large B-cell Lymphoma

Mostafa Faisal: ASCT Remains Effective for Chemotherapy-Sensitive Late Relapse in DLBCL

 

Ajay K. Gopal Alex F. Herrera cancer Craig S Sauter Leona Holmberg Lorenzo Iovino Mazyar Shadman Mehdi Hamadani Mohamed A. Kharfan-Dabaja Mostafa Faisal Ningxin Ma OncoDaily Oncology Peter A. Riedell Qian Vicky Wu Sonali M. Smith